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1032-121 Utility of B-Type Natriuretic Peptide Assay in the 
Assessment of Symptomatic State in Hypertrophic 
Cardiomyopathy
Barry J. Maron, Venkatakrishna N. Tholakanahalli, Susan A. Casey, Andrey G. Zenovich, 
Daniel Duprez, Dorothee M. Aeppli, Jay N. Cohn, Minneapolis Heart Institute 
Foundation, Minneapolis, MN, University of Minnesota Medical School, Minneapolis, MN
Background. Hypertrophic cardiomyopathy (HCM) is a common genetic cardiovascular
disease with a diverse clinical spectrum which often includes functional disability due to
progressive heart failure symptoms at any age. Assessment of symptom severity may be
highly subjective and encumbered by the heterogenous clinical presentation of HCM.
Plasma B-type natriuretic peptide (BNP) has been used widely as an objective marker for
the severity of heart failure and clinical outcome predominantly in coronary heart disease
with ventricular dilatation and systolic dysfunction. We considered the possibility that
BNP would be an accurate and independent predictor of heart failure severity in HCM, a
disease characterized by intact ventricular function in the absence of chamber dilatation.
Methods. We prospectively assessed plasma BNP as a quantitative clinical marker of
heart failure severity in 107 consecutive HCM patients.
Results. BNP showed a statistically significant relationship to the magnitude of functional
limitation assessed by New York Heart Association (NYHA) functional class: I: 136 ± 159
pg/ml; II: 338 ± 439 pg/ml; III/IV: 481 ± 334 pg/ml (p < 0.001). Multivariable analysis
showed BNP was independently related to NYHA functional class (p = 0.003), as well as
age (p = 0.0001) and left ventricular wall thickness (p = 0.0001). BNP power was consid-
erable both in distinguishing patients with and without heart failure symptoms, or for dif-
ferentiating between no (or only mild) symptoms and severe symptoms (area under
receiver opearting curve = 0.75 and 0.83, respectively). A BNP cut-off value > 200 pg/ml
was the most reliable predictor of heart failure symptoms with positive and negative pre-
dictive values of 65% and 79%, respectively.
Conclusions. Plasma BNP is independently related to the presence and magnitude of
heart failure-related symptoms in patients with HCM. The clinical power of BNP as a
marker for heart failure in HCM is, however, restricted by the overlap in BNP values
between symptom-related subgroups, due largely to the important confounding variables
of advancing age and substantial left ventricular wall thickness characteristic of this het-
erogeneous disease.
1032-122 Comprehensive Mutational Analysis of Myosin Binding 
Protein C in 389 Unrelated Patients With Hypertrophic 
Cardiomyopathy
Sara L. Van Driest, Steve R. Ommen, Vlad C. Vasile, Melissa L. Will, A. Jamil Tajik, 
Bernard J. Gersh, Michael J. Ackerman, Mayo Clinic, Rochester, MN
Background: Mutations in myosin binding protein C (MYBPC3) represent the most com-
mon genetic cause of hypertrophic cardiomyopathy (HCM). MYBPC3-HCM has been
associated with late onset of disease and benign course. Here, we determine the fre-
quency, spectrum, and phenotype associated with MYBPC3-HCM in a cohort of unre-
lated patients evaluated at a single tertiary outpatient center.
Methods: DNA was obtained from 389 unrelated HCM patients and analyzed for muta-
tions in all 34 protein coding exons of MYBPC3 using polymerase chain reaction, dena-
turing high performance liquid chromatography, and direct DNA sequencing. Clinical data
were extracted from patient records blinded to genotype.
Results: Seventy-six patients (19.5%) were identified with 49 MYBPC3 mutations: 24
missense, 15 frameshift, 6 premature stop, 3 splice-site, and 1 in-frame deletion. Muta-
tion type did not influence the clinical phenotype. Compared to patients without MYBPC3
mutations, patients with MYBPC3-HCM were younger at diagnosis (35.4 ± 15 years vs
42.7 ± 19 years, p = 0.002), more often had a family history of HCM (44.7% vs 27.2%, p
= 0.004), and more often received an ICD (26.3% vs 12.8%, p = 0.003). When comparing
patients with single MYBPC3 mutations (n=67) to those with single mutations involving
either the beta myosin heavy chain (MYH7) or the light chains comprising the thick fila-
ment (n=60), there was no difference in age, symptoms at presentation, or degree of
hypertrophy. However, patients with MYBPC3 mutations were less likely to undergo sur-
gical myectomy than patients with thick filament mutations (34% vs 55%, p = 0.02).
Conclusion: This study represents a comprehensive mutational analysis of the most
common HCM-causing gene, MYBPC3, in the largest cohort of unrelated patients.
Nearly 1 in 5 patients presenting to this tertiary HCM center had MYBPC3 mutations.
Contrary to genotype-phenotype correlations derived from family studies, unrelated
patients with MYBPC3-HCM were diagnosed at a younger age than those patients with
no MYBPC3 mutation. Moreover, the only difference in phenotypic expression between
MYBPC3-HCM and thick filament-HCM was likelihood of surgical myectomy.
1032-123 Mechanisms for Left Ventricular Outflow Tract 
Obstruction After Initial Septal Myectomy for 
Obstructive Hypertrophic Cardiomyopathy
Kenji Minakata, Joseph A. Dearani, Hartzell V. Schaff, Patrick W. O'Leary, Steve R. 
Ommen, Gordon K. Danieslon, Mayo Clinic and Foundation, Rochester, MN
Objectives; Septal myectomy provides excellent outcomes for most patients with severe
obstructive hypertrophic cardiomyopathy (HCM). However, in a few patients, left ventricu-
lar outflow tract obstruction (LVOTO) may recur or persist after myectomy, requiring
repeat myectomy. We reviewed this subset to assess the mechanisms for recurrence or
persistence of LVOTO.
Methods; From 1975 to July 2003, 610 septal myectomies were performed by the authors
for obstructive HCM; 13 of these were repeat myectomies for recurrent or persistent
LVOTO after myectomies performed at our institution (n=6) or elsewhere (n=7). Six
patients were age 16 years or younger at the reoperation. The mean interval between ini-
tial myectomy and repeat myectomy was 5.0+/-3.7 years.
Results; At reoperation, mechanisms for obstruction included septal hypertrophy at mid-
ventricular level (n=8), anomalous papillary muscles (n=3), and incomplete subaortic
resection at the initial operation (n=11). Mean intraoperative peak systolic pressure gradi-
ents decreased from 68+/-34 to 6.9+/-5.1 mmHg after repeat myectomy. No mitral valve
replacement was performed. An iatrogenic ventricular septal defect in one patient was
successfully repaired. Mean follow-up was 5.8 years. There were no early deaths; one
patient died 11 years after repeat myectomy at age 81. All surviving patients were in
NYHA functional class I or II and free of significant LVOTO.
Conclusions; Dynamic LVOTO may recur or persist after classic septal myectomy in a
small number of patients. Repeat myectomy can be performed with excellent outcomes.
Need for reoperation may be reduced with current surgical approaches which include a
more extended resection of the mid-ventricular septum, relief of papillary muscle anoma-
lies, and routine use of intraoperative transesophageal echocardiography.
1032-124 Coronary Microvascular Dysfunction and Long-Term 
Left Ventricular Remodeling in Hypertrophic 
Cardiomyopathy
Iacopo Olivotto, Franco Cecchi, Roberto Gistri, Roberto Lorenzoni, Giampaolo Chiriatti, 
Daniela Vargiu, Paolo G. Camici, Azienda Ospedaliera Careggi, Florence, Italy, 
Hammersmith Hospital, Imperial College, London, United Kingdom
Background. Left ventricular (LV) remodeling in adult patients with hypertrophic cardi-
omyopathy (HCM) is characterized by cavity enlargement, systolic dysfunction and wall
thinning, occasionally progressing to overt systolic heart failure. To ascertain whether LV
remodeling is related to coronary microvascular dysfunction, we assessed the relation-
ship between absolute myocardial blood flow (MBF) and long-term echocardiographic
changes in HCM patients. Methods. Fifty-one HCM patients (NYHA class I-II) were fol-
lowed for 8.1±2.1 years following a baseline echocardiogram and PET for measurement
of resting and dypiridamole MBF (Dip-MBF). Twelve controls were assessed for compari-
son. LV remodeling was defined by >1 of three previously published criteria: end-diastolic
dimension >52 mm, fractional shortening 5 mm. The “End-stage” phase was defined as
LV remodeling associated with clinical deterioration to NYHA class III-IV. Results. Resting
MBF did not differ between patients and controls (0.84±0.31 vs. 1.00±0.23 ml/min/g;
p=0.10) whereas Dip-MBF was severely blunted in patients (1.50±0.69 versus 2.71±0.94
ml/min/g; p<0.001). At the end of follow-up, 18 patients (35%), showed evidence of LV
remodeling, including 7 in end-stage (14%; with 2 heart failure deaths and 2 patients
evaluated for transplant). LV remodeling occurred 2.5-fold more frequently in the lowest
tertile of Dip-MBF (0.59-1.11 ml/min/g) as compared to each other tertile (p=0.09 at sur-
vival analysis); moreover, 6 out of 7 end-stage patients were in this lowest tertile
(p=0.005). At multivariate analysis, the two independent predictors of end-stage progres-
sion were Dip-MBF in the lowest tertile (OR 17.3, 95% CI: 1.7-177.1; p=0.016) and end-
diastolic LV dimensions >45 mm (OR 13.5, 95% CI: 1.3-140.7; p=0.029). Conclusions.
Severe microvascular dysfunction was strongly associated with long-term end stage pro-
gression in HCM patients, particularly when associated with initial evidence of LV dilata-
tion. Conversely, patients with milder degrees of LV remodeling showed a weaker
association with Dip-MBF impairment, suggesting a role for other pathophysiological trig-
gers.
1032-125 Electrocardiographic Pattern of Giant Negative T Wave 
in Hypertrophic Cardiomyopathy: Is It a Specific Feature 
of “Apical” Hypertrophic Cardiomyopathy ?
Makoto Okawa, Hiroaki Kitaoka, Yoshihisa Matsumura, Toru Kubo, Naohito Yamasaki, 
Takashi Furuno, Jun Takata, Yoshinori Doi, Barry J. Maron, Kochi Medical School, 
Nankoku, Japan, Minneapolis Heart Institute Foundation, Minneapolis, MN
Background: Striking electrocardiographic (ECG) pattern of “giant negative T wave
(GNT)” defined as >10mm deep in the left precordial leads was reported as a hallmark of
apical form of hypertrophic cardiomyopathy (HCM), in which hypertrophy is confined to
the most distal region of the left ventricular (LV) apex. However, the prevalence of GNT in
apical HCM varies in Japan and Western countries. It can also be found in patients with
typical HCM with asymmetric septal hypertrophy (ASH).
Purpose: To clarify the morphological characteristics of HCM patients with GNT, and to
elucidate the relationship between apical HCM and GNT.
Methods and Results: Among 147 HCM patients, we identified 43 patients with GNT.
Echocardiography revealed three distinct morphologic pattern of LV hypertrophy. (1)
Hypertrophy is confined to the apex below papillary muscle level. (apical HCM: pure
form) (n=14) (2) Apical hypertrophy is extended to ventricular septum, without basal sep-
tal hypertrophy. (mixed form) (n=5) (3) Typical HCM presenting ASH. (ASH) (n=24) Com-
parison among these three groups is shown on the table. The prevalence of GNT was
64% (14/22) in pure apical HCM, and 23% (29/125) in HCM after excluding apical HCM
of pure form.
Conclusion: HCM patients with ECG pattern of GNT consist of morphologically heteroge-
neous subgroups (pure apical HCM, mixed form, ASH), and GNT is not a specific feature
of pure apical HCM. Patients with apical HCM may have milder clinical presentation, dif-
ferent from those with mixed form or ASH with GNT.
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1032-126 Effects of Alcohol Septal Ablation Versus Surgical 
Myectomy on the Cardiac Conduction System
Deepak R. Talreja, Rick A. Nishimura, Steve R. Ommen, A. J. Tajik, David R. Holmes, 
Mayo Clinic, Rochester, MN
Background: Permanent pacing for heart block is a complication of current septal reduc-
tion procedures for patients with hypertrophic cardiomyopathy (HCM). These procedures
have separate anatomic effects on the conduction system and knowledge of these differ-
ences may identify patients at higher risk for heart block.
Methods: We examined medical records of patients with HCM who underwent percuta-
neous alcohol-septal ablation (ASA, n=52) or surgical myectomy (SM, n=131) at the
Mayo Clinic from July 1999 through August 2003. Pre- and post-procedural electrocardio-
grams were compared.
Results: Of the 52 patients who underwent ASA, 5 (8%) were paced before the proce-
dure and were excluded from further analysis. Of the 6 (13%) who required permanent
pacing after ASA, 2 had LBBB prior to the procedure and an additional 3 had LAD with
increased QRS duration. Of the 131 pts who underwent SM, 13 were excluded due to
prior pacing. Of the 8 patients (7%) who required permanent pacing after SM, 3 of these
had RBBB prior to the procedure. The right bundle was affected in 47% of patients after
ASA and 4% of patients after SM while the left bundle was affected in no patients after
ASA and 42% of patients after SM.
Conclusion: ASA selectively affects the anterior septum resulting in RBBB, while SM
produces an endocardial lesion in the inferior septal region that is more likely to result in
LBBB. Therefore, patients with baseline RBBB are more likely to need long-term pacing
after SM while those with LBBB are more likely to need pacing after ASA. 
1032-127 Regression of Hypertrophy in Remote Myocardium After 
Percutaneous Transluminal Septal Myocardial Ablation 
in Hypertrophic Obstructive Cardiomyopathy: A 
Magnetic Resonance Imaging Follow-Up Study
Willem G. van Dockum, Marco J.W Gotte, Aernout M. Beek, Folkert J. ten Cate, Jurrien 
M. ten Berg, Mark B.M Hofman, Cees A. Visser, Albert C. van Rossum, VU University 
Medical Center, Amsterdam, The Netherlands, Erasmus Medical Center, Rotterdam, The 
Netherlands
Background: Percutaneous transluminal septal myocardial ablation (PTSMA) in symp-
tomatic patients with hypertrophic obstructive cardiomyopathy reduces the left ventricular
(LV) outflow tract obstruction and decreases LV wall stress. The purpose of this study
was to evaluate the early effects of PTSMA on regional myocardial thickness and
regional myocardial mass with MRI. 
Methods: In twenty-seven patients (age 52±15 years) MR imaging was performed at
baseline and at one and six-month’s follow-up after PTSMA. With contrast-enhanced
(CE-)MRI infarct size and location were determined. Changes in regional wall thickness,
LV volumes and regional myocardial mass were evaluated using cine imaging.
Results: After PTSMA, no infarction-related hyperenhancement was found outside the
target area using CE-MRI. In patients with a successful gradient reduction (n=24), end-
diastolic septal thickness at the infarct site decreased from 2.0±0.4 cm at baseline to
1.3±0.2 cm and 0.9±0.3 cm at 1 and 6 month’s follow-up, respectively (p<0.001). Also the
anterior, lateral and inferior wall thickness decreased significantly at both 1 and 6 month’s
(p<0.05 and p<0.001, resp.). As LV end-diastolic volumes remained unchanged, and LV
end-systolic volumes increased (p<0.001), ejection fraction decreased from 69±5% to
65±5% at 6 month’s (p<0.001). Total LV myocardial mass decreased from 207±52 to
190±49 g (– 8%) and 165±42 (– 20%) at 1 and 6 month’s, respectively (p<0.001). Septal
mass decreased from 73±22 g to 64±19 g (– 12%) at 1 month and to 57±17 g (– 22%) at
6 month’s (p<0.001). The reduction of remote mass was significant at both 1 and 6
month’s follow-up (p<0.001), indicating early LV remodeling.
Conclusion: Septal ablation therapy in HOCM results in early LV remodeling with
increased end-systolic volumes, normalization of EF, and regression of the remote myo-
cardial hypertrophy.
1032-128 AMP Kinase Disease in Hypertrophic Cardiomyopathy: 
Evidence for a Multisystem Storage Disorder
Ross T. Murphy, Jens Mogensen, Ajay Bahl, Toru Kobu, Janice Holton, Perry M. Elliott, 
Kate McGarry, William J. McKenna, The Heart Hospital, London, United Kingdom
Background: Mutations in the gene for AMP-activated protein kinase (PRKAG2) have
recently been described as disease-causing in hypertrophic cardiomyopathy (HCM). We
set out to investigate the prevalence and clinical expression of AMP Kinase disease in
patients with typical and atypical HCM drawn from a large clinical cohort of 1468 HCM
patients.
Methods: Mutation analysis of PRKAG2 was performed by fluorescent SSCP analysis
and direct sequencing of abnormal conformers. Clinical evaluation including electrocar-
diography (EKG), echocardiography, Holter monitoring and metabolic exercise testing
was performed. Skeletal muscle biopsy was performed where appropriate.
Results: Mutation screening of unselected and selected cohorts of HCM patients identi-
fied only one de-novo mutation, in addition to two previously identified families with
PRKAG2 mutations.
Mean age at clinical diagnosis in the 45 gene carriers was 24 years (median 20, range 9-
55). Symptoms of palpitations, dypspnea, chest pain or syncope were present in 31
(69%) of gene carriers. Seven patients (15%) complained of myalgia and had evidence of
proximal myopathy. The EKG pattern was characterized by left ventricular hypertrophy
(LVH) with bizarre QRS pattern, short PR interval, and/or delta waves. Disease pene-
trance defined by EKG abnormalities was 100% above the age of 18. Thirty-two of 41
adults (78%) had left ventricular hypertrophy on echocardiography (mean maximal wall
thickness: 21mm (range: 13-40).
Survival rate was 91% at a mean follow-up of 12.2 years. Progressive conduction dis-
ease was identified leading to pacemaker implant in 17/45 (38%) mutation carriers at a
mean age of 38 years. Of patient > 18 years at first assessment, there was slowly pro-
gressive LVH on echocardiography in 78%. Skeletal muscle biopsy showed excess mito-
chondria and ragged red fibres with glycogen accumulation. Functional muscle studies
are discussed.
Conclusions: Disease pattern is characterized by progressive conduction disease requir-
ing pacing, progressive cardiac hypertrophy and includes extra-cardiac manifestations
such as a skeletal myopathy, consistent with a systemic metabolic storage disease.
1032-129 By Relieving Obstruction, Disopyramide Increases 
Extent and Duration of Systolic Shortening in 
Obstructive Hypertrophic Cardiomyopathy: A Doppler 
Tissue Imaging Study
Shrikanth P. Upadya, Ivan Barac, Vilma Casteneda, Michael Passick, Farooq A. 
Chaudhry, Mark Sherrid, St. Luke- Roosevelt Hospital, New York, NY
Background: Disopyramide relieves left ventricular outflow (LVOT) gradient and
improves symptoms in obstructive hypertrophic cardiomyopathy(OHCM). Doppler tissue
imaging (DTI) has shown premature cessation and reduced extent of longitudinal systolic
shortening in OHCM which corresponds to a mid-systolic drop (MSD) in left ventricle (LV)
ejection velocity- the lobster claw abnormality. Changes in DTI after disopyramide treat-
ment in OHCM are unknown.
Methods: Eleven patients with OHCM who were treated with disopyramide(age=68 ±15,
8 females) were selected as systolic gradient decreased to less than 60 mm Hg after 4.7
+ 4.7 days. Long axis DTI was performed from the apex to record the mitral annular
velocities at the basal septum and the basal lateral wall. Offline measurement of DTI
determined the velocity time integral (VTI), peak systolic velocity, and duration of systole,
calculated as the time from the beginning of the QRS to the end of the systole on the DTI
trace. Results: Results are shown in Table. After disopyramide reduction of gradient,
there was significant increase in the VTI of the septum, VTI of the lateral wall and the
septal systolic duration. This corresponds to a disappearance of the MSD.
Conclusions: Relief of obstruction causes an increase in the duration and excursion of
the systolic longitudinal LV contraction. This confirms that MSD is caused by the prema-
ture cessation of longitudinal shortening in mid-systole and that the abnormalities of
shortening are reversible.
HCM with GNT
Pure apical HCM
(n=14)
Mixed form
(n=5)
ASH with GNT
(n=24)
Age at diagnosis
(years)
54+-16 61+-12 52+-14
Male 93% (13) 100% (5) 83% (20)
Family history 7% (1) 40% (2) 38% (9)
Max LV thickness
(mm)
18+-2 18+-2 20+-5
NYHA III-IV 0% (0) 0% (0) 7% (2)
Table
Parameters Pre- treatment Post- treatment p value
Heart rate 76 ± 20 63 ± 12 0.029
LVOT gradient 123 ± 41 14 ± 20 0.00002
Mitral regurgitation
1.2 ± 1 0.55 ± 0.5
0.026
Septal VTI (cm)
1.25 ± 0.5
1.85 ± 0.42 0.00005
PSV- Septal (cm /sec.) 8.67 ± 1.85 7.66 ± 1.26 0.22
Sytolic duration - Septal (msec.) 274 ± 9.9 356 ± 5.2 0.027
Lateral VTI (cm) 1.65 ± 0.33 1.91 ± 0.42 0.005
PSV- Lateral (cm/sec.) 8.57 ± 1.78 9.79 ± 2.4 0.16
Systolic duration ( msec.) 386 ± 4.6 392 ± 4 0.15
